Medicinal Chemistry of Incretin Mimetics and DPP‐4 Inhibitors
Authors:
- 26 January 2010
- journal article
- review article
- Published by Wiley in ChemMedChem
- Vol. 5 (2) , 179-185
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 DiabetesDiabetes Care, 2009
- Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogueMolecular and Cellular Endocrinology, 2009
- Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular DomainJournal of Biological Chemistry, 2008
- The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteersBritish Journal of Clinical Pharmacology, 2007
- Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in HumansDrug Metabolism and Disposition, 2007
- Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??MellitusClinical Pharmacokinetics, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- ExenatideAmerican Journal of Health-System Pharmacy, 2006
- Structure and function studies of glucagon‐like peptide‐1 (GLP‐1): the designing of a novel pharmacological agent for the treatment of diabetesDiabetes/Metabolism Research and Reviews, 2005
- Proline specific peptidasesBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1997